Back to Journals » Drug Design, Development and Therapy » Volume 9

Profile of delamanid for the treatment of multidrug-resistant tuberculosis

Authors Szumowski J, Lynch J

Received 13 November 2014

Accepted for publication 6 January 2015

Published 29 January 2015 Volume 2015:9 Pages 677—682

DOI https://doi.org/10.2147/DDDT.S60923

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 5

Editor who approved publication: Professor Shu-Feng Zhou


John D Szumowski,1,2 John B Lynch1

1Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA; 2Division of AIDS Medicine, Santa Clara Valley Medical Center, San Jose, CA, USA

Abstract: New approaches to the treatment of multidrug-resistant and extensively drug-resistant tuberculosis (TB) are badly needed. Not only is the success rate of current treatment regimens suboptimal but existing regimens require multiple drugs and lengthy courses and may lead to significant toxicities. The treatment landscape is beginning to shift, however, with the recent approvals of the new TB drugs bedaquiline and delamanid. Delamanid, a dihydro-imidazooxazole, has been shown to have excellent activity against Mycobacterium tuberculosis in both in vitro and in murine TB models. It has also recently been reported to improve rates of sputum culture conversion in patients with multidrug-resistant TB when added to an optimized background regimen. Although generally well tolerated, delamanid has been associated with QT prolongation, which may be of particular clinical concern when paired with other TB drugs that may also have this effect, most notably the fluoroquinolones. Ongoing studies will help to clarify delamanid’s role in the treatment of drug-resistant TB.

Keywords: delamanid, OPC-67683, Deltyba, tuberculosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]